Ascorbyl Palmitate / PI3K Cancer Research Results

AsP, Ascorbyl Palmitate: Click to Expand ⟱
Features:
Ascorbyl palmitate is an ester formed from ascorbic acid and palmitic acid creating a fat-soluble form of vitamin C. Ascorbyl palmitate is a highly bioavailable, fat-soluble form of ascorbic acid (vitamin C) and possesses all the properties of native water-soluble counterpart, that is vitamin C.

Ascorbyl Palmitate — Ascorbyl palmitate (AP; also called L-ascorbyl palmitate, vitamin C palmitate) is the 6-O-palmitate ester of L-ascorbic acid, used primarily as a lipid-phase antioxidant/preservative (food additive E304(i), INS 304(i)) and in topical/cosmetic formulations. It is an amphipathic, fat-soluble vitamin C derivative that localizes to lipid interfaces and can be enzymatically hydrolyzed to ascorbic acid + palmitate (extent and site depend on formulation and biology). In the Nestronics index (pid 35), AP is linked to limited cancer-pathway annotations largely derived from a small nanoformulation literature rather than broad clinical oncology deployment.

Primary mechanisms (ranked):

  1. Lipid-phase antioxidant activity (radical scavenging; inhibition of lipid peroxidation at membranes/oil–water interfaces)
  2. Membrane redox modulation with possible pro-oxidant behavior under specific conditions (secondary; model-/matrix-dependent)
  3. IL-6/STAT3 signaling suppression with downstream anti-proliferative and pro-apoptotic effects (preclinical; prominent in AP nanoformulations)
  4. Anti-angiogenic signaling effects reported in tumor models (e.g., VEGF/NO axis; preclinical)
  5. Anti-migration/invasion effects (e.g., MMP-related readouts; preclinical)

Bioavailability / PK relevance: As a fatty acid ester, AP partitions into dietary and biological lipids; oral exposure is formulation-dependent and it is generally believed to undergo esterase-mediated hydrolysis to ascorbic acid plus palmitate. Human oncology-relevant systemic PK for intact AP is not well standardized in the open literature; most “therapeutic” claims rely on delivery systems (e.g., solid lipid nanoparticles) rather than conventional oral supplement dosing.

In-vitro vs systemic exposure relevance: Many mechanistic cancer studies use micromolar-to-millimolar in-vitro concentrations and/or nano-enabled delivery that can exceed typical systemic levels achievable from food-additive exposure; translation hinges on formulation, local delivery, and tumor targeting rather than simple oral dosing.

Clinical evidence status: Predominantly preclinical (in vitro/in vivo) and largely formulation-driven (nano/SLN platforms). No established role as an anticancer drug in routine clinical oncology; clinical use is mainly as an antioxidant excipient/food additive.

Ascorbyl Palmitate — Mechanistic Pathway Matrix (Cancer Context)

Rank Pathway / Axis Cancer Cells Normal Cells TSF Primary Effect Notes / Interpretation
1 Lipid peroxidation control ↓ lipid peroxidation (context-dependent) ↓ lipid peroxidation P Antioxidant stabilization of lipid phases Core identity is a lipid-phase antioxidant used to protect fats/oils and membranes; mechanistic centrality is redox buffering rather than direct oncogene targeting.
2 ROS balance ↔ (model-dependent; can be pro-oxidant at high concentration or in specific matrices) ↔ (model-dependent) P Redox modulation Some datasets (including food-matrix and additive evaluations) note condition-dependent pro-oxidant behavior; interpret as context- and co-antioxidant–dependent rather than a fixed direction.
3 IL-6 / STAT3 axis ↓ (preclinical; strongest in nanoformulations) Unknown / not established R Anti-proliferative signaling shift STAT3↓ and IL6↓; primary open literature support clusters around AP nanoformulations reporting STAT3 pathway inhibition with tumor growth suppression.
4 Apoptosis ↑ (preclinical; formulation-dependent) ↔ / safety generally favorable at permitted exposures R Programmed cell death induction Often downstream of stress + signaling changes (e.g., STAT3 suppression) in tumor models; not a validated clinical anticancer mechanism for standard oral exposure.
5 Cell cycle regulation ↓ proliferation / cell-cycle arrest (model-dependent) ↔ G Growth suppression Reported G2/M arrest appears in AP nanoparticle studies; treat as secondary to upstream stress/signaling.
6 Angiogenesis / NO signaling ↓ VEGF / ↓ NO (preclinical) ↔ (context-dependent) G Anti-angiogenic phenotype VEGF↓/NO↓/angioG↓; evidence is not broad across tumor types and appears tied to specific experimental systems.
7 Migration / invasion ↓ MMP-related invasion signals (preclinical) ↔ G Reduced metastatic traits MMP9↓ and TumMeta↓; mechanistic specificity remains limited outside a small formulation-driven literature.
8 NRF2 axis ↔ (not clearly established as a primary AP mechanism) ↔ G Secondary antioxidant-response tuning Unlike many electrophilic polyphenols, AP’s primary chemistry is radical scavenging in lipid phases; NRF2 involvement (if present) is typically indirect and context-driven.
9 Clinical Translation Constraint Formulation-driven exposure requirement Food-additive exposures are low — Limits on oncology leverage Regulatory acceptance is for antioxidant use (GMP/food additive contexts), but oncology-relevant effects mostly rely on nano/targeted delivery; intact-AP systemic PK and tumor delivery are the main bottlenecks.

TSF legend: P: 0–30 min   R: 30 min–3 hr   G: >3 hr
PI3K, Phosphatidylinositide-3-Kinases: Click to Expand ⟱
Source: HalifaxProj(inhibit) CGL-CS
Type:
Phosphatidylinositol 3-kinase (PtdIns3K or PI3K) is a family of enzymes that play a crucial role in cell signaling pathways, particularly in the regulation of cell growth, survival, and metabolism. The PI3K pathway is one of the most frequently altered pathways in human cancer. Inhibition of the PI3K pathway has been explored as a therapeutic strategy for cancer treatment. Several PI3K inhibitors have been developed and are currently being tested in clinical trials. These inhibitors can target specific components of the pathway, such as PI3K, AKT, or mTOR.

Class I phosphoinositide 3-kinase (PI3K)
Class III PtdIns3K
In contrast to the class III PtdIns3K as a positive regulator of autophagy, class I PI3K-AKT signaling has an opposing effect on the initiation of autophagy.

PI3K inhibitors include:
-Idelalisib , Copanlisib, Alpelisib
-LY294002?
-Wortmannin: potent PI3K inhibitor, has some associated toxicity.
-Quercetin:
-Curcumin
-Resveratrol
-Epigallocatechin Gallate (EGCG)
Scientific Papers found: Click to Expand⟱
5389- AsP,  Tras,    ASCORBYL PALMITATE ENHANCES ANTI-PROLIFERATIVE EFFECT OF TRASTUZUMAB IN HER2-POSITIVE BREAST CANCER CELLS
tumCV↓, eff↑, P53↑, BAX↑, Casp3↑, Casp8↑, Bcl-2↓, Apoptosis↑, p‑p38↓, ERK↓, PI3K↓,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:


Cell Death ⓘ

Apoptosis↑, 1,   BAX↑, 1,   Bcl-2↓, 1,   Casp3↑, 1,   Casp8↑, 1,   p‑p38↓, 1,  

Transcription & Epigenetics ⓘ

tumCV↓, 1,  

DNA Damage & Repair ⓘ

P53↑, 1,  

Proliferation, Differentiation & Cell State ⓘ

ERK↓, 1,   PI3K↓, 1,  

Drug Metabolism & Resistance ⓘ

eff↑, 1,  
Total Targets: 11

Pathway results for Effect on Normal Cells:


Total Targets: 0

Scientific Paper Hit Count for: PI3K, Phosphatidylinositide-3-Kinases
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:35  Target#:252  State#:%  Dir#:1
  wNotes=0  sortOrder:rid,rpid

 

Home Page